Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3

Cell Death and Disease

Volumn 4, Issue 6, 2013, Pages

  Lai, F ^a   Guo, S T ^b   Jin, L ^a   Jiang, C C ^a   Wang, C Y ^b   Croft, A ^c   Chi, M N ^a   Tseng, H Y ^a   Farrelly, M ^a   Atmadibrata, B ^d   Norman, J ^d   Liu, T ^d   Hersey, P ^e   Zhang, X D ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SHANXI CANCER HOSPITAL   (China)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CASPASE 3; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE; LIPOCORTIN 5; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PANOBINOSTAT; PROPIDIUM IODIDE; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 1; RECEPTOR INTERACTING PROTEIN KINASE 3; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VEMURAFENIB; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MELANOMA; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

MURINAE;

EID: 84879668461     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.192     Document Type: Article

References (60)

1. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11: 873-886.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
3. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012; 132: 854-863.
4. Smalley KS, Sondak VK. Melanoma-an unlikely poster child for personalized cancer therapy. N Engl J Med 2010; 363: 876-878.
5. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-255.
6. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-977.
7. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-390.
8. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009; 106: 20411-20416.
9. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-695.
10. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2011; 17: 721-730.
11. Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. NF-kB as potential target in the treatment of melanoma. J Transl Med 2012; 10: 53.
12. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
13. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 782-789.
14. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 773-781.
15. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012; 18: 2316-2325.
16. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012; 18: 2502-2514.
17. Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis 2010; 1: e69.
18. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010; 8: 39.
19. Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ 2012; 19: 2029-2039.
20. Wroblewski D, Mijatov B, Mohana-Kumaran N, Lai F, Gallagher SJ, Haass NK et al. The BH3 mimetic ABT-737 sensitises human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis 2012; 34: 237-247.
21. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 2007; 13: 4934-4942.
22. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
23. Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006; 32: 157-165.
24. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009; 100: 28-36.
25. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F et al. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008; 18: 274-278.
26. Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD et al. A phase I pharmacokinetic study of pulse-dose SAHA with flavopiridol in solid tumors. Invest New Drugs 2011; 29: 1004-1012.
27. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009; 69: 8693-8699.
28. Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 2005; 18: 160-166.
29. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004; 3: 425-435.
30. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-18035.
31. Garcia-Morales P, Gomez-Martinez A, Carrato A, Martinez-Lacaci I, Barbera VM, Soto JL et al. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 2005; 4: 1222-1230.
32. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19: 75-86.
33. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives? Nat Rev Cancer 2012; 12: 411-424.
34. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signalling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
35. Wang Z, Jiang H, Chen S, Du F, Wang X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 2012; 148: 228-243.
36. Lai F, Jin L, Gallagher S, Mijatov B, Zhang XD, Hersey P. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Adv Pharmacol 2012; 65: 27-43.
37. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001; 61: 7339-7348.
38. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 2001; 8: 588-594.
39. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010; 8: 31.
40. Gillespie S, Zhang XD, Hersey P. Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Mol Cancer Ther 2005; 4: 668-676.
41. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: 1318-1325.
42. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
43. Vandenabeele P, Grootjans S, Callewaert N, Takahashi N. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models. Cell Death Differ 2013; 20: 185-187.
44. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
45. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2010; 22: 263-268.
46. Moujalled DM, Cook WD, Okamoto T, Murphy J, Lawlor KE, Vince JE et al. TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. Cell Death Dis 2013; 4: e465.
47. Kalai M, Van Loo G, Vanden Berghe T, Meeus A, Burm W, Saelens X et al. Tipping the balance between necrosis and apoptosis in human and murine cells treated with interferon and dsRNA. Cell Death Differ 2002; 9: 981-994.
48. Hersey P, Zhuang L, Zhang XD. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int Rev Cytol 2006; 251: 131-158.
49. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16: 1093-1107.
50. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 2007; 9: 440-451.
51. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-410.
52. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
53. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
54. Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One 2011; 6: e23209.
55. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-a feedforward signaling. Cell 2011; 145: 92-103.
56. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-10838.
57. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-3645.
58. Lo SC, Hannink M. PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redoxregulated Keap1-dependent ubiquitin ligase complex. J Biol Chem 2006; 281: 37893-37903.
59. Zhan Z, Li Q, Wu P, Ye Y, Tseng HY, Zhang L et al. Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy 2012; 8: 109-121.
60. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H et al. Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 2011; 30: 3716-3726.